1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

19 Jul 2024
Admin
News Article

CytoMed Acquires Cord Blood Banking License to Enhance Allogeneic γδ T Cells Technology

CytoMed Therapeutics Acquires Cord Blood Banking License and Assets to Enhance Allogeneic γδ T Cells Technology for Solid and Liquid Cancer Treatments

Overview

CytoMed Therapeutics Limited (NASDAQ: GDTC), a Singapore-based biopharmaceutical company, has acquired Cellsafe International Sdn Bhd (In Liquidation) (“CISB”), a Malaysian cord blood bank, for approximately RM 2.3 million or US$ 490,000. This acquisition includes a cord blood banking license issued by Malaysia’s Ministry of Health, cryopreservation equipment with over 12,000 cord blood units (“CBUs”), and two freehold real estate properties totaling 189 square meters.

CytoMed’s Expertise

CytoMed aims to leverage its expertise in developing γδ T cells from three sources: adult peripheral blood mononuclear cells, induced Pluripotent Stem Cells (iPSCs), and now, cord blood.
Historically seen as medical waste, cord blood has gained significance in cell therapies, particularly for cancer treatment and anti-aging applications.

CytoMed plans to Innovation

• Traditionally, cord blood banks have primarily focused on cryopreserving CBUs for hematopoietic stem cell transplants in blood disorders, limited by factors like haplotype matching and cell adequacy.

• CytoMed plans to innovate by expanding the use of CBUs to treat a broader range of conditions, including solid cancers, using advanced stem cell technologies.

Behind Acquisition

The acquisition aligns with CytoMed’s strategy to unlock the therapeutic potential of umbilical cord blood, enhancing its position in developing cytotoxic γδ T cells for cancer therapy.
This move marks a significant shift in the traditional business model of cord blood banking, aiming to repurpose cryopreserved assets for advanced therapeutic applications.

From CytoMed

CytoMed, expressed, “This acquisition is a strategic step towards harnessing umbilical cord blood’s therapeutic potential and advancing γδ T cell technology for cancer treatment.”
Dr. Tan Wee Kiat, Co-CEO, highlighted the potential of mononuclear cells in CBUs as a versatile raw material for various cell therapies, emphasizing the focus on immune T cells to combat both hematological and solid cancers.

CytoMed’s Proprietary Technologies & Patents

CytoMed’s proprietary technologies and licensed patents, including the recently granted iPSC-derived hybrid γδ NKT cells technology targeting solid and hematological cancers, position the company at the forefront of innovative cancer therapies. This patent underscores CytoMed’s commitment to developing effective, targeted therapies using advanced cell science.

Future Plans: CytoMed

Looking ahead, CytoMed plans to expand its capabilities and seek strategic partnerships to grow its subsidiary focused on umbilical cord blood-derived immune cell banking, emphasizing γδ T cells and NK cells for cancer treatment.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!